Tatjana Pandzic
- E-mail:
- tatjana.pandzic@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
Medical Genetics at Department of Immunology, Genetics and Pathology; Clinical units; Clinical genetics
- E-mail:
- tatjana.pandzic@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 Uppsala
More information is available to staff who log in.
Publications
Recent publications
- Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML (2024)
- Micro-costing of genetic diagnostics in acute leukemia in Sweden (2024)
- Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation (2024)
- BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib (2023)
- Familial platelet disorder due to germline exonic deletions in RUNX1 (2022)
All publications
Articles
- Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML (2024)
- Micro-costing of genetic diagnostics in acute leukemia in Sweden (2024)
- Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation (2024)
- BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib (2023)
- Familial platelet disorder due to germline exonic deletions in RUNX1 (2022)
- Loss of Y and clonal hematopoiesis in blood (2022)
- Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting (2022)
- Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy (2022)
- Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia (2021)
- Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma (2020)
- Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome (2020)
- Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression (2020)
- Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 (2019)
- Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations (2018)
- Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity (2017)
- Loss of DIP2C in RKO cells stimulates changes in DNA methylation and epithelial-mesenchymal transition (2017)
- Somatic PRDM2 c.4467delA mutations in colorectal cancers control histone methylation and tumor growth (2017)
- Whole-exome sequencing in relapsing chronic lymphocytic leukemia (2016)
- Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma (2016)
- Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia (2016)
- DISSECTING RESISTANCE MECHANISMS IN CHRONIC LYMPHOCYTIC LEUKEMIA USING WHOLE-EXOME SEQUENCING (2015)
- Computational and molecular tools for scalable rAAV-mediated genome editing (2015)
- MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool (2014)
- Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing (2013)
- N-Acyl Taurines are Anti-Proliferative in Prostate Cancer Cells (2012)
- Clonal evolution patterns in high-risk chronic lymphocytic leukemia treated with ibrutinib